Genyro

Executive Summary

Genyro is a synthetic biology company leveraging AI and machine learning to transform DNA into a predictable, programmable building material. Founded in 2019 and headquartered in San Francisco, the company aims to shift biology from an experimental science to a robust engineering infrastructure. By turning genetic sequences into functional systems and designs into living constructs, Genyro seeks to enable rapid, reliable design of organisms for applications in therapeutics, materials, and sustainability. While specific funding and valuation data are not yet public, the company's focus on AI-driven design and DNA synthesis positions it at the forefront of the emerging biofoundry sector. Genyro's platform could significantly reduce the iteration time and cost of biological engineering, unlocking new possibilities for bio-based production. However, as a private, early-stage company, it faces typical challenges in scaling, regulatory navigation, and commercial adoption. The overall market opportunity is substantial, with synthetic biology projected to grow rapidly over the next decade.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement70% success
• Q2 2027Platform Commercial Launch or Key Partnership50% success
• Q1 2027First Product Prototype or Proof-of-Concept Publication60% success